RYBREVANT®
(amivantamab-vmjw)
RYBREVANT® (amivantamab-vmjw)
RYBREVANT - pivotal clinical trial publications
CHRYSALIS
Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021. 39(30):3391-3402.
PAPILLON
Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389:2039-2051.
Zhou C, Tang KJ, Cho BC, et al. Supplementary Appendix for: Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389:2039-2051.
MARIPOSA
Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC [published online ahead of print June 26, 2024]. N Engl J Med. 2024. doi:10.1056/nejmoa2403614.
Cho BC, Lu S, Felip E, et al. Supplementary Appendix for: Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC [published online ahead of print June 26, 2024]. N Engl J Med. 2024. doi:10.1056/nejmoa2403614.
MARIPOSA-2
Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.
Passaro A, Wang J, Wang Y, et al. Supplementary Appendix for: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.
Plain language summaries of pivotal clinical trials
CHRYSALIS
Spira A, Girard N, Krebs M, et al. A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncol. 2023;19(33):2213-2225.
PAPILLON
Sabari JK, Girard N, Mansfield AS, et al. Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR-mutated non-small-cell lung cancer [published online ahead of print July 16, 2024] Future Oncol. 2024. doi: 10.1080/14796694.2024.2371698
MARIPOSA
Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2024.18(6):639-647.
MARIPOSA-2
Passaro A, Wang J, Wang Y, et al. Plain Language Summary for: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.